Compare CSTE & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CSTE | EVAX |
|---|---|---|
| Founded | 1987 | 2008 |
| Country | Israel | Denmark |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.7M | 31.9M |
| IPO Year | 2012 | 2020 |
| Metric | CSTE | EVAX |
|---|---|---|
| Price | $1.42 | $4.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $11.67 |
| AVG Volume (30 Days) | ★ 2.8M | 27.7K |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.43 | N/A |
| Revenue Next Year | $2.83 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $1.25 |
| 52 Week High | $3.26 | $12.15 |
| Indicator | CSTE | EVAX |
|---|---|---|
| Relative Strength Index (RSI) | 63.06 | 59.06 |
| Support Level | $1.42 | $2.70 |
| Resistance Level | $1.75 | $4.64 |
| Average True Range (ATR) | 0.16 | 0.34 |
| MACD | 0.08 | 0.03 |
| Stochastic Oscillator | 96.32 | 65.83 |
Caesarstone Ltd manufactures engineered quartz surfaces. Its products include engineered quartz and porcelain slabs, which are used as kitchen countertops in renovation and remodeling, and residential construction. It also has other applications, including vanity tops, wall panels, backsplashes, floor tiles, stairs, and other interior surfaces that are used in various residential and non-residential applications. The company sells its products under the Caesarstone brand. Caesarstone's geographical segments are the United States, Canada, Latin America, Australia, Asia, Israel, and EMEA(Europe, Middle East, Africa).
Evaxion AS is a clinical-stage TechBio company developing novel vaccines with its proprietary, clinically validated and scalable AI platform, AI-Immunology. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases for patients in the market. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients' lives by providing inventive and targeted treatment options.